Canarslan Demir Kubra, Avci Ahmet Ugur, Ozgok Kangal Munire Kubra, Ceylan Berrin, Abayli Selcen Yusra, Ozler Ismail, Yilmaz Kerim Bora
Department of Undersea and Hyperbaric Medicine, Gulhane Research and Training Hospital, University of Health Sciences, 06010 Ankara, Turkey.
Department of Aerospace Medicine, Gulhane Research and Training Hospital, University of Health Sciences, 06010 Ankara, Turkey.
Medicina (Kaunas). 2025 Feb 22;61(3):385. doi: 10.3390/medicina61030385.
Hyperbaric oxygen therapy (HBOT) has shown promise in managing complications due to cancer treatments, particularly those related to radiotherapy and surgery. Despite its clinical benefits, concerns persist regarding its potential to influence cancer progression. This study aimed to evaluate the safety and clinical outcomes of HBOT in patients with active or previously treated solid tumors. A retrospective analysis was conducted on patients with solid tumors who underwent at least five HBOT sessions. Comprehensive data, including patient demographics, cancer type, total number of HBOT sessions, imaging findings, and clinical outcomes (recurrence, metastasis, and mortality), were collected. Descriptive statistics and the relationship between the number of HBOT sessions and long-term cancer outcomes were analyzed. This study included 45 patients (median age: 64 years; 60% male) who received a median of 27 HBOT sessions. At initiation, 27.9% of the patients were classified as cured, 53.5% were in remission, and 18.6% had active cancer. Over a median follow-up period of 783 days, 8.7% experienced recurrence, 2.7% had persistent active cancer, and 59.5% had no recurrence. No HBOT-related complications were observed during the course of HBOT. Statistical analyses revealed no significant correlations between the number of HBOT sessions and metastasis ( = 0.213) or mortality ( = 0.881). HBOT appears to be a safe and effective adjunctive therapy for managing complications in patients with solid tumors. No evidence was found to suggest HBOT contributes to tumor progression, recurrence, or metastasis. Future prospective studies with larger cohorts are needed to confirm these results and further evaluate the therapeutic role of HBOT in oncology.
高压氧疗法（HBOT）在处理癌症治疗引起的并发症方面已显示出前景，特别是那些与放疗和手术相关的并发症。尽管其具有临床益处，但人们对其影响癌症进展的可能性仍存在担忧。本研究旨在评估HBOT对患有活动性或既往接受过治疗的实体瘤患者的安全性和临床结局。对接受至少五次HBOT治疗的实体瘤患者进行了回顾性分析。收集了包括患者人口统计学、癌症类型、HBOT治疗总次数、影像学检查结果和临床结局（复发、转移和死亡率）在内的综合数据。分析了描述性统计数据以及HBOT治疗次数与长期癌症结局之间的关系。本研究纳入了45例患者（中位年龄：64岁；60%为男性），他们接受的HBOT治疗次数中位数为27次。开始时，27.9%的患者被分类为治愈，53.5%处于缓解期，18.6%患有活动性癌症。在中位随访期783天内，8.7%的患者出现复发，2.7%患有持续性活动性癌症，59.5%未复发。在HBOT治疗过程中未观察到与HBOT相关的并发症。统计分析显示，HBOT治疗次数与转移（ = 0.213）或死亡率（ = 0.881）之间无显著相关性。HBOT似乎是一种安全有效的辅助治疗方法，可用于处理实体瘤患者的并发症。未发现证据表明HBOT会促进肿瘤进展、复发或转移。需要未来进行更大样本量的前瞻性研究来证实这些结果，并进一步评估HBOT在肿瘤学中的治疗作用。
